National Comprehensive Cancer Network (NCCN) guidelines recommend carboplatin + (paclitaxel or albumin-bound paclitaxel) + pembrolizumab as first-line treatment for advanced or metastatic LSCC patients with PD-L1 tumor proportion score ≥1% and a performance status of 0 to 2.[7] Besides PD-L1, TMB is a potential immunotherapy biomarker. The gene discussed is CD274; the disease is neoplasm.